[go: up one dir, main page]

WO2000075291A3 - Cells with enforced expression of bcl-xl - Google Patents

Cells with enforced expression of bcl-xl Download PDF

Info

Publication number
WO2000075291A3
WO2000075291A3 PCT/EP2000/005195 EP0005195W WO0075291A3 WO 2000075291 A3 WO2000075291 A3 WO 2000075291A3 EP 0005195 W EP0005195 W EP 0005195W WO 0075291 A3 WO0075291 A3 WO 0075291A3
Authority
WO
WIPO (PCT)
Prior art keywords
bcl
cells
enforced
enforced expression
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/005195
Other languages
French (fr)
Other versions
WO2000075291A2 (en
Inventor
Oksana Ivanivna Sirenko
Michael Paul Cooke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfindungen Verwaltungs GmbH, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Priority to AU54031/00A priority Critical patent/AU5403100A/en
Publication of WO2000075291A2 publication Critical patent/WO2000075291A2/en
Publication of WO2000075291A3 publication Critical patent/WO2000075291A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to genetically modified CD34+ hematopoietic cells which overexpress a BCL-XL protein, cell populations comprising such cells and their medical uses. The present invention also relates to methods of enforced BCL-XL expression in hematopoietic cells. Such enforced expression results in an increase in hematopoietic cell viability, expansion, and engraftment ability.
PCT/EP2000/005195 1999-06-08 2000-06-06 Cells with enforced expression of bcl-xl Ceased WO2000075291A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54031/00A AU5403100A (en) 1999-06-08 2000-06-06 Enforced expression of bcl-xl

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32830899A 1999-06-08 1999-06-08
US09/328,308 1999-06-08

Publications (2)

Publication Number Publication Date
WO2000075291A2 WO2000075291A2 (en) 2000-12-14
WO2000075291A3 true WO2000075291A3 (en) 2001-06-28

Family

ID=23280443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005195 Ceased WO2000075291A2 (en) 1999-06-08 2000-06-06 Cells with enforced expression of bcl-xl

Country Status (2)

Country Link
AU (1) AU5403100A (en)
WO (1) WO2000075291A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1414996T3 (en) * 2001-07-10 2011-03-21 Johnson & Johnson Res Pty Ltd Methods for Genetically Modifying Hematopoietic Progenitor Cells and Uses of Modified Cells
EP1348758A1 (en) * 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Host cells having improved cell survival properties and methods to generate such cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014853A1 (en) * 1994-11-10 1996-05-23 University Of Washington Intrathymic stem cell implantation
WO1996017627A2 (en) * 1994-12-09 1996-06-13 Mosca Joseph D System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014853A1 (en) * 1994-11-10 1996-05-23 University Of Washington Intrathymic stem cell implantation
WO1996017627A2 (en) * 1994-12-09 1996-06-13 Mosca Joseph D System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
IMAIZUMI KAZUNORI ET AL: "The cell death-promoting gene DP5, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid beta protein.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 12, 19 March 1999 (1999-03-19), pages 7975 - 7981, XP002156341, ISSN: 0021-9258 *
KONOPLEVA M ET AL: "Overexpression of antiapoptotic Bcl-XL and Bcl-2 contributes to chemoresistance of quiescent leukemic progenitors and can be selectively reversed by ATRA.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), 40th Annual Meeting of the American Society of Hematology;Miami Beach, Florida, USA; December 4-8, 1998, pages 600A - 601A, XP000971741, ISSN: 0006-4971 *
KONOPLEVA M ET AL: "The antiapoptotic genes BCL-XL and BCL-2 are overexpressed in quiescent leukemic progenitor cells.", BLOOD, vol. 90, no. 10 SUPPL. 1 PART 1, 15 November 1997 (1997-11-15), 39th Annual Meeting of the American Society of Hematology;San Diego, California, USA; December 5-9, 1997, pages 558A, XP000971742, ISSN: 0006-4971 *
MARSHALL WILLIAM L ET AL: "U937 cells overexpressing bcl-xl are resistant to human immunodeficiency virus-1-induced apoptosis and human Immunodeficiency virus-1 replication.", VIROLOGY, vol. 256, no. 1, 30 March 1999 (1999-03-30), pages 1 - 7, XP002156340, ISSN: 0042-6822 *
SANTIAGO-SCHWARZ, FRANCES ET AL: "In vitro expansion of CD13+CD33+ dendritic cell precursors from multipotent progenitors is regulated by a discrete fas-mediated apoptotic schedule", J. LEUKOCYTE BIOL. (1997), 62(4), 493-502, XP000971740 *

Also Published As

Publication number Publication date
AU5403100A (en) 2000-12-28
WO2000075291A2 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
EP2048228A3 (en) Human liver progenitors
EP2033514A3 (en) Carbon Monoxide Improves Outcomes in Cell and Organ Transplants and Suppresses Apoptosis
WO2000024365A8 (en) Treatment of skin with adenosine or adenosine analog
EP2289939A3 (en) PAN-KIR2DL NK-receptor antibodies and their use in diagnostic and therapy
EP2278022A3 (en) Expression vectors, transfection systems, and method of use thereof
CA2390281A1 (en) Hematopoietic differentiation of human embryonic stem cells
BR0312764A (en) Functional cardiomyocytes from human embryonic stem cells
AU9582398A (en) Methods and devices for the long-term culture of hematopoietic progenitor cells
CA2442135A1 (en) Methods to culture circovirus
GB2392674A (en) Mesenchymal cells and osteoblasts from human embryonic stem cell
IL148008A0 (en) Conditional immortalisation of cells
IL132951A0 (en) Compounds preparation and use for transferring nucleic acids into cells
WO2000001231A8 (en) Improved methods for storing neural cells
ATE324030T1 (en) BRASSICA TRANSFORMATION THROUGH PARTICLE Bombardment
WO2008036421A3 (en) Reishi-mediated enhancement of human tissue progenitor cell adhesion and differentiation
GB9825096D0 (en) Cells,culture methods and their uses
IL139435A0 (en) Antibodies to dendritic cells and human dendritic cell populations and uses thereof
BR0314402A (en) Ex vivo expansion of root cell populations in mononuclear cell cultures
CA2227241A1 (en) Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
AU687623B2 (en) Cell Adhesion peptides for use in modifying mutual adhesion among eukaryotic cells
WO2000075291A3 (en) Cells with enforced expression of bcl-xl
AU5168099A (en) Use of novel agents inducing cell death in synergy with interferons
ZA200200340B (en) Storage of microorganisms, cells and tissue.
GB2379446A (en) Cells,culture methods and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP